247 related articles for article (PubMed ID: 25160667)
1. Minimizing morbidity of hypoglycemia in diabetes: a review of mini-dose glucagon.
Chung ST; Haymond MW
J Diabetes Sci Technol; 2015 Jan; 9(1):44-51. PubMed ID: 25160667
[TBL] [Abstract][Full Text] [Related]
2. Mini-dose glucagon rescue for hypoglycemia in children with type 1 diabetes.
Haymond MW; Schreiner B
Diabetes Care; 2001 Apr; 24(4):643-5. PubMed ID: 11315823
[TBL] [Abstract][Full Text] [Related]
3. Mini-doses of glucagon to prevent hypoglycemia in children with type 1 diabetes refusing food: a case series.
Tinti D; Rabbone I
Acta Diabetol; 2020 Mar; 57(3):359-365. PubMed ID: 31673895
[TBL] [Abstract][Full Text] [Related]
4. Mini-Dose Glucagon as a Novel Approach to Prevent Exercise-Induced Hypoglycemia in Type 1 Diabetes.
Rickels MR; DuBose SN; Toschi E; Beck RW; Verdejo AS; Wolpert H; Cummins MJ; Newswanger B; Riddell MC;
Diabetes Care; 2018 Sep; 41(9):1909-1916. PubMed ID: 29776987
[TBL] [Abstract][Full Text] [Related]
5. Effects of subcutaneous, low-dose glucagon on insulin-induced mild hypoglycaemia in patients with insulin pump treated type 1 diabetes.
Ranjan A; Schmidt S; Madsbad S; Holst JJ; Nørgaard K
Diabetes Obes Metab; 2016 Apr; 18(4):410-8. PubMed ID: 26743775
[TBL] [Abstract][Full Text] [Related]
6. Factors influencing the effectiveness of glucagon for preventing hypoglycemia.
Castle JR; Engle JM; El Youssef J; Massoud RG; Ward WK
J Diabetes Sci Technol; 2010 Nov; 4(6):1305-10. PubMed ID: 21129324
[TBL] [Abstract][Full Text] [Related]
7. Glucagon treatment in type 1 diabetes -with focus on restoring plasma glucose during mild hypoglycemia
.
Ranjan A
Dan Med J; 2018 Feb; 65(2):. PubMed ID: 29393039
[TBL] [Abstract][Full Text] [Related]
8. Nonaqueous, Mini-Dose Glucagon for Treatment of Mild Hypoglycemia in Adults With Type 1 Diabetes: A Dose-Seeking Study.
Haymond MW; Redondo MJ; McKay S; Cummins MJ; Newswanger B; Kinzell J; Prestrelski S
Diabetes Care; 2016 Mar; 39(3):465-8. PubMed ID: 26861921
[TBL] [Abstract][Full Text] [Related]
9. Efficacy determinants of subcutaneous microdose glucagon during closed-loop control.
Russell SJ; El-Khatib FH; Nathan DM; Damiano ER
J Diabetes Sci Technol; 2010 Nov; 4(6):1288-304. PubMed ID: 21129323
[TBL] [Abstract][Full Text] [Related]
10. Relationship between Optimum Mini-doses of Glucagon and Insulin Levels when Treating Mild Hypoglycaemia in Patients with Type 1 Diabetes - A Simulation Study.
Ranjan A; Wendt SL; Schmidt S; Madsbad S; Holst JJ; Madsen H; Knudsen CB; Jørgensen JB; Nørgaard K
Basic Clin Pharmacol Toxicol; 2018 Mar; 122(3):322-330. PubMed ID: 28922582
[TBL] [Abstract][Full Text] [Related]
11. New Fast Acting Glucagon for Recovery from Hypoglycemia, a Life-Threatening Situation: Nasal Powder and Injected Stable Solutions.
La Sala L; Pontiroli AE
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638984
[TBL] [Abstract][Full Text] [Related]
12. Intranasal glucagon: a promising approach for treatment of severe hypoglycemia.
Pontiroli AE
J Diabetes Sci Technol; 2015 Jan; 9(1):38-43. PubMed ID: 25385946
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Mini-Dose Glucagon for Treatment of Nonsevere Hypoglycemia in Adults With Type 1 Diabetes.
Haymond MW; DuBose SN; Rickels MR; Wolpert H; Shah VN; Sherr JL; Weinstock RS; Agarwal S; Verdejo AS; Cummins MJ; Newswanger B; Beck RW;
J Clin Endocrinol Metab; 2017 Aug; 102(8):2994-3001. PubMed ID: 28591776
[TBL] [Abstract][Full Text] [Related]
14. Dasiglucagon, a next-generation ready-to-use glucagon analog, for treatment of severe hypoglycemia in children and adolescents with type 1 diabetes: Results of a phase 3, randomized controlled trial.
Battelino T; Tehranchi R; Bailey T; Dovc K; Melgaard A; Yager Stone J; Woerner S; von dem Berge T; DiMeglio L; Danne T
Pediatr Diabetes; 2021 Aug; 22(5):734-741. PubMed ID: 33934456
[TBL] [Abstract][Full Text] [Related]
15. Intranasal versus injectable glucagon for hypoglycemia in type 1 diabetes: systematic review and meta-analysis.
Pontiroli AE; Tagliabue E
Acta Diabetol; 2020 Jun; 57(6):743-749. PubMed ID: 32025860
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic and Pharmacodynamic Characteristics of Dasiglucagon, a Novel Soluble and Stable Glucagon Analog.
Hövelmann U; Bysted BV; Mouritzen U; Macchi F; Lamers D; Kronshage B; Møller DV; Heise T
Diabetes Care; 2018 Mar; 41(3):531-537. PubMed ID: 29273578
[TBL] [Abstract][Full Text] [Related]
17. An Evaluation of Glucagon Injection Anxiety and Its Association with the Fear of Hypoglycemia among the Parents of Children with Type 1 Diabetes.
Muradoğlu S; Yeşiltepe Mutlu G; Gökçe T; Can E; Hatun Ş
J Clin Res Pediatr Endocrinol; 2021 Aug; 13(3):285-292. PubMed ID: 33491925
[TBL] [Abstract][Full Text] [Related]
18. Mini-dose glucagon rescue for mild hypoglycaemia in children with type 1 diabetes: the Brisbane experience.
Hartley M; Thomsett MJ; Cotterill AM
J Paediatr Child Health; 2006 Mar; 42(3):108-11. PubMed ID: 16509909
[TBL] [Abstract][Full Text] [Related]
19. Effects of Preceding Ethanol Intake on Glucose Response to Low-Dose Glucagon in Individuals With Type 1 Diabetes: A Randomized, Placebo-Controlled, Crossover Study.
Ranjan A; Nørgaard K; Tetzschner R; Steineck IIK; Clausen TR; Holst JJ; Madsbad S; Schmidt S
Diabetes Care; 2018 Apr; 41(4):797-806. PubMed ID: 29358493
[TBL] [Abstract][Full Text] [Related]
20. Long-term non-surgical therapy of severe persistent congenital hyperinsulinism with glucagon.
Mohnike K; Blankenstein O; Pfuetzner A; Pötzsch S; Schober E; Steiner S; Hardy OT; Grimberg A; van Waarde WM
Horm Res; 2008; 70(1):59-64. PubMed ID: 18493152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
